Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Levels of Natural Antibodies Before and After Immunoglobulin Replacement Treatment Affect the Clinical Phenotype in Common Variable Immunodeficiency ; volume:45 ; number:1 ; day:21 ; month:9 ; year:2024 ; pages:1-10 ; date:12.2025
Journal of clinical immunology ; 45, Heft 1 (21.9.2024), 1-10, 12.2025
- Urheber
-
Sarrigeorgiou, Ioannis
Tsinti, Gerasimina
Kalala, Fani
Germenis, Anastasios
Speletas, Matthaios
Lymberi, Peggy
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10875-024-01805-7
- URN
-
urn:nbn:de:101:1-2412160935188.278091062466
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sarrigeorgiou, Ioannis
- Tsinti, Gerasimina
- Kalala, Fani
- Germenis, Anastasios
- Speletas, Matthaios
- Lymberi, Peggy
- SpringerLink (Online service)
Ähnliche Objekte (12)
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
Protective anti‐prion antibodies in human immunoglobulin repertoires
Anaphylaxis to IGIV in immunoglobulin-naïve common variable immunodeficiency patient in the absence of IgG anti-IgA antibodies: successful administration of low IgA-containing immunoglobulin
A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
Antifungal antibodies present in intravenous immunoglobulin derived from China
Immunomodulatory and anti‐inflammatory properties of immunoglobulin G antibodies
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin
Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
Protective anti‐prion antibodies in human immunoglobulin repertoires
Anaphylaxis to IGIV in immunoglobulin-naïve common variable immunodeficiency patient in the absence of IgG anti-IgA antibodies: successful administration of low IgA-containing immunoglobulin
A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
Antifungal antibodies present in intravenous immunoglobulin derived from China
Immunomodulatory and anti‐inflammatory properties of immunoglobulin G antibodies
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin
Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
Protective anti‐prion antibodies in human immunoglobulin repertoires
Anaphylaxis to IGIV in immunoglobulin-naïve common variable immunodeficiency patient in the absence of IgG anti-IgA antibodies: successful administration of low IgA-containing immunoglobulin
A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
Antifungal antibodies present in intravenous immunoglobulin derived from China
Immunomodulatory and anti‐inflammatory properties of immunoglobulin G antibodies
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin